Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Operating Expenses (2017 - 2024)

Solid Biosciences' Operating Expenses history spans 8 years, with the latest figure at $39.9 million for Q4 2024.

  • For Q4 2024, Operating Expenses rose 79.19% year-over-year to $39.9 million; the TTM value through Dec 2024 reached $129.7 million, up 24.44%, while the annual FY2024 figure was $129.7 million, 24.44% up from the prior year.
  • Operating Expenses for Q4 2024 was $39.9 million at Solid Biosciences, up from $35.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $39.9 million in Q4 2024 and bottomed at $19.0 million in Q2 2020.
  • The 5-year median for Operating Expenses is $25.0 million (2023), against an average of $26.1 million.
  • The largest annual shift saw Operating Expenses tumbled 35.59% in 2023 before it surged 79.19% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $21.3 million in 2020, then grew by 2.15% to $21.8 million in 2021, then soared by 58.52% to $34.6 million in 2022, then crashed by 35.59% to $22.3 million in 2023, then soared by 79.19% to $39.9 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Operating Expenses are $39.9 million (Q4 2024), $35.2 million (Q3 2024), and $27.8 million (Q2 2024).